Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;4(4):288-297.
doi: 10.1007/s40471-017-0124-x. Epub 2017 Oct 17.

Estimating Effects of Dynamic Treatment Strategies in Pharmacoepidemiologic Studies with Time-varying Confounding: A Primer

Affiliations

Estimating Effects of Dynamic Treatment Strategies in Pharmacoepidemiologic Studies with Time-varying Confounding: A Primer

Xiaojuan Li et al. Curr Epidemiol Rep. 2017 Dec.

Abstract

Purpose of review: Pharmacoepidemiologists are often interested in estimating the effects of dynamic treatment strategies, where treatments are modified based on patients' evolving characteristics. For such problems, appropriate control of both baseline and time-varying confounders is critical. Conventional methods that control confounding by including time-varying treatments and confounders in an outcome regression model may not have a causal interpretation, even when all baseline and time-varying confounders are measured. This problem occurs when time-varying confounders are, themselves, affected by past treatment. We review alternative analytic approaches that can produce valid inferences in the presence of such confounding. We focus on the parametric g-formula and inverse probability weighting of marginal structural models, two examples of Robins' g-methods.

Recent findings: Unlike standard outcome regression methods, the parametric g-formula and inverse probability weighting of marginal structural models can estimate the effects of dynamic treatment strategies and appropriately control for measured time-varying confounders affected by prior treatment. Few applications of g-methods exist in the pharmacoepidemiology literature, primarily due to the common use of administrative claims data, which typically lack detailed measurements of time-varying information, and the limited availability of or familiarity with tools to help perform the relatively complex analysis. These barriers may be overcome with the increasing availability of data sources containing more detailed time-varying information and more accessible learning tools and software.

Summary: With appropriate data and study design, g-methods can improve our ability to make causal inferences on dynamic treatment strategies from observational data in pharmacoepidemiology.

Keywords: Causal Inference; Dynamic Treatment Strategies; G-methods; Pharmacoepidemiology; Time-varying Confounding.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Xiaojuan Li received support for this work through a Thomas O. Pyle Fellowship from the Harvard Medical School & Harvard Pilgrim Health Care Institute. Jessica G. Young is supported by a faculty grant from the Harvard Pilgrim Health Care Institute. Sengwee Toh is also supported by the National Institute of Biomedical Imaging and Bioengineering (U01EB023683).

Figures

Figure 1
Figure 1. A simplified graphic depiction of an observational pharmacoepidemiologic study with measured time-varying confounders affected by past treatment
The schematic represents a screenshot of two observational intervals during follow-up.
Figure 2
Figure 2. A graphical depiction of bias due to conditioning on a confounder for future treatment effects that is also affected by past treatment
Standard regression methods include time-dependent anemia parameters m in the model, resulting in a biased estimate of the causal effect of iron treatment m − 1 on mortality due to an induced association with unmeasured hemochromatosis.

References

    1. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20. - PubMed
    1. Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1–6. - PubMed
    1. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period—application to the healthy worker survivor effect. Mathematical Modelling. 1986;7(9–12):1393–512.
    1. Murphy SA, van der Laan MJ, Robins JM. Marginal mean models for dynamic regimes. J Am Stat Assoc. 2001;96(456):1410–23. - PMC - PubMed
    1. Macdougall IC, Bircher AJ, Eckardt K-U, Obrador GT, Pollock CA, Stenvinkel P, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;89(1):28–39. - PubMed

LinkOut - more resources